Evigrade
Major

Ketorolac × meloxicam

Non-steroidal anti-inflammatory drugs (NSAIDs)×NSAID, COX-2 preferential, oxicam derivative

Mechanism

Dual NSAID therapy – additive GI bleeding and nephrotoxicity risk. Despite meloxicam's preferential COX-2 selectivity, GI toxicity adds up when combined with ketorolac.

Symptoms

Black or tarry stools, vomiting blood, epigastric pain. Risk multiplies in older patients and with prior peptic ulcer disease.

Management

The combination is not prescribed. One NSAID at a time. Ketorolac courses no more than 5 days. For enhanced analgesia: paracetamol or a short opioid.

Sources

All interactions